Natalie Lieber's practice focuses on complex patent litigation in a wide variety of technologies and contested proceedings before the United States Patent Office, including inter partes review. Her litigation work has involved technologies such as small molecule pharmaceuticals, formulations, smartphones, network security appliances, mobile DTV transmitters, quality of service monitoring for wireless networks, filters for semiconductor applications, and marine electronics. She has been a member of trial teams in federal courts across the country as well as the International Trade Commission.
While in law school, Ms. Lieber served on the editorial board of the Moot Court Honor Society.
Mylan Pharmaceuticals Inc. v. Gilead Sciences, Inc.
Natalie was on the team who represented Gilead when they defeated Mylan’s inter-partes review directed to four patents protecting blockbuster HIV therapies. This was the first time, the USPTO had denied institution of trials on all challenged claims in an inter partes review of patents protecting pharmaceutical salts and prodrugs.